TissueGen

TransTissue, founded as a spin-off of the University Hospital Charité in February 2000, has been a subsidiary of the BioTissue Group since September 2001. Our goal is to transfer theory into clinical practice. TransTissue is part of a worldwide network of international cooperations with interdisciplinary academic partners and industry. TransTissue rapidly transfers laboratory processes into standardized and controlled procedures for producing tissue engineering and advanced therapy medicinal products as well as medical devices in compliance with GMP guidelines. At TransTissue Technologies we are focused on inventions and new methods for tissue regeneration, leading to novel Tissue Engineering products and new platform technologies. Our vision is to establish regenerative medicine in daily clinical life. TransTissue, founded as a spin-off of the University Hospital Charité in February 2000, has been a subsidiary of the BioTissue Group since September 2001. With more than 20 years of experience in the field of tissue engineering and regenerative medicine, the scientists and founders of TransTissue have developed third-generation autologous tissue replacements, e.g.

BioTissue, a double spin-off of the Charité University Hospital in Berlin and the University Hospital in Freiburg, is the pioneer par excellence in the field of regenerative medicine and tissue engineering. BioTissue’s technology platform offers unique solutions to improve quality of life by intelligently harnessing the body’s own regenerative potential through implants that can be applied with minimally invasive surgical procedures. BioTissue has focused on two areas of regenerative medicine to offer orthobiological solutions for cartilage defects:. This innovative field of advanced biomedical technologies provides therapies to regenerate damaged tissues or organs. In order to continuously expand our technological lead, we have founded our own development company.

BioTissue is the leader in innovative technologies using products derived from human amniotic membrane tissues. In 1997, BioTissue was the first company to introduce the use of cryopreserved amniotic membrane tissue for clinical application, by utilizing its proprietary CryoTek technology, proven to preserve the innate biological and structural properties of the amniotic membrane tissue. By adopting the BioTissue name across the entire organization, the company will also reflect that innovative heritage and promise in its surgical business, which was previously known as Amniox Medical. BioTissue is pursuing FDA approval through submission of a Biologics License Applications (BLA) for some of our products as evidenced in a recently published Phase 2 study for complex diabetic foot ulcers.20 Our company will continue to provide sustainable health economic value, solve unmet clinical needs, and lead in technological innovation in seeking to deliver the promise of regenerative healing for our physicians and patients. Our extensive research allows us to preserve and deliver the most functional allograft for your needs. We empower healthcare professionals to deliver optimal patient healing outcomes, setting the standards that define next-generation care. TissueTech was founded in 2001 as the parent entity for BioTissue Inc., which develops and markets regenerative therapies for treating the ocular surface. In 2011, our company expanded from ocular space and its product offerings that, include Prokera®, AmnioGraft® and AmnioGuard® to additional market segments such as orthopedics,14-16 neuropathy,17 wound care,18-23 spine,24 urology25, and pain management26,27 using the same birth tissue products processed using our patented manufacturing technology.

TissueGUARD GmbH was founded as a spin-off from the Leibniz Institute of Polymer Research Dresden (IPF), Germany. Therefore, TissueGUARD founders developed a biocompatible, on-demand degradable cell culture platform, which can overcome these obstacles – the basis for our innovative technology. Today, TissueGUARD has several patents in the pipeline targeting the next generation of tissue engineering and cell therapies. We are a tight-knit team continually looking for new opportunities for growth and development. TissueGUARD develops smart hydrogel-based medical devices for the next generation of regenerative therapies. The TissueGUARD team is a dedicated team of scientists and engineers joined together to deliver innovative devices and biotechnology. TissueGUARD develops novel biotechnology solutions and devices for tissue engineering, organoid therapeutics, and cell therapies. TissueGUARD is committed to enabling novel regenerative therapies via innovative biotechnologies and medical devices.

TissueForm improves life for people affected by volumetric tissue loss by harnessing the natural, restorative power of extracellular matrix to correct and repair defects or injuries with a novel, regenerative biomaterial. Our core technology combines a natural tissue powder and biocompatible gel for stabilized crosslinking at human body temperature. Our biomaterial fills volumetric defects, integrates with host tissue, and promotes healing.

Our vision is to establish Tissue Regenix Group as a leader in the science and innovation of regenerative medicine. We are committed to transforming patient care and delivering favourable health economic outcomes. Tissue Regenix Group is a pioneering, international medical technology company, focusing on the development of regenerative products. Regenerative medicine is an innovative and expanding field, researching the potential of tissue engineering to offer a natural recovery by triggering a response through the body’s own cells, and enable the natural regeneration of the patient’s own tissues. We use our innovative platform technologies to address clinical needs in the regenerative medicine market. We focus on the development of regenerative products utilising our two platform technologies to transform the treatment of patients and provide differentiated clinical outcomes in key clinical areas. Our business model enables us to generate value for our stakeholders and deliver differentiated clinical outcomes. Tissue Regenix’s vision to become a leader in regenerative medicine is underpinned by its core values to maintain a sustainable, ethical and responsible company.